ORIC Pharmaceuticals (ORIC) News Today $8.80 -0.16 (-1.79%) (As of 09:30 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Fmr LLC Decreases Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Fmr LLC reduced its position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 11.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,378,819 shares of the company's stock after selling 541,54December 8, 2024 | marketbeat.comArrowMark Colorado Holdings LLC Acquires 80,986 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)ArrowMark Colorado Holdings LLC lifted its holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 6.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,354,508 shares of the company's stock afterDecember 3, 2024 | marketbeat.comFred Alger Management LLC Has $2.25 Million Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Fred Alger Management LLC boosted its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 40.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 219,447 shares of the company's stock after purchasing an aDecember 2, 2024 | marketbeat.comAlkeon Capital Management LLC Has $40.02 Million Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Alkeon Capital Management LLC lifted its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 2.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,904,096 shares of the company's stock after buying an additioNovember 29, 2024 | marketbeat.comORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 25, 2024 | globenewswire.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Recommendation of "Buy" from AnalystsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) has been assigned an average recommendation of "Buy" from the eight ratings firms that are presently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average 12-month price taNovember 23, 2024 | marketbeat.comFirst Turn Management LLC Sells 64,923 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)First Turn Management LLC lessened its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 4.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,451,037 shares ofNovember 19, 2024 | marketbeat.comResearch Analysts Issue Forecasts for ORIC FY2024 EarningsORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Investment analysts at Cantor Fitzgerald decreased their FY2024 earnings estimates for shares of ORIC Pharmaceuticals in a research note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst P. Agrawal now anticipates tNovember 18, 2024 | marketbeat.comFY2024 EPS Estimate for ORIC Pharmaceuticals Cut by AnalystORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Investment analysts at Wedbush decreased their FY2024 EPS estimates for ORIC Pharmaceuticals in a report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($1.82) per shNovember 15, 2024 | marketbeat.comOric Pharmaceuticals Reports Strong Financial Growth and Clinical ProgressNovember 14, 2024 | markets.businessinsider.comOppenheimer Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)November 13, 2024 | markets.businessinsider.comORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational UpdatesNovember 13, 2024 | markets.businessinsider.comPositive Outlook on ORIC-114: Promising Preclinical Results and Selective Efficacy Bolster Buy RatingNovember 5, 2024 | markets.businessinsider.comORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 4, 2024 | globenewswire.comORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 5.2% - Here's What HappenedORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 5.2% - Time to Sell?November 4, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $21.00 target price on shares of ORIC Pharmaceuticals in a report on Monday.November 4, 2024 | marketbeat.comWells Fargo Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Overweight RecommendationNovember 1, 2024 | msn.comORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | globenewswire.comJones Trading Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Buy RecommendationNovember 1, 2024 | msn.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Here's What HappenedORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Should You Buy?October 31, 2024 | marketbeat.comOric Pharmaceuticals initiated with a Buy at JonesResearchOctober 31, 2024 | markets.businessinsider.comORIC Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Analysts at Wells Fargo & CompanyWells Fargo & Company initiated coverage on ORIC Pharmaceuticals in a research note on Thursday. They set an "overweight" rating and a $20.00 price objective for the company.October 31, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 8.4% - Should You Buy?ORIC Pharmaceuticals (NASDAQ:ORIC) Trading 8.4% Higher - Should You Buy?October 29, 2024 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Recommendation of "Buy" from BrokeragesShares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have been assigned a consensus recommendation of "Buy" from the seven analysts that are presently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average twelvOctober 29, 2024 | marketbeat.comOric Pharmaceuticals presents data on ORIC-114October 24, 2024 | markets.businessinsider.comCandid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of DirectorsOctober 17, 2024 | finance.yahoo.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading 4.5% Higher - Still a Buy?ORIC Pharmaceuticals (NASDAQ:ORIC) Trading 4.5% Higher - Here's What HappenedOctober 14, 2024 | marketbeat.comSG Americas Securities LLC Takes $714,000 Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)SG Americas Securities LLC bought a new stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 69,620 shares of the company's stock, valueOctober 14, 2024 | marketbeat.comMillennium Management LLC Boosts Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Millennium Management LLC grew its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 297.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 782,299 shares of the company's stock afOctober 12, 2024 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Bought by Dimensional Fund Advisors LPDimensional Fund Advisors LP lifted its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 190.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 466,662 shares of the company's stock after buying an aOctober 11, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsOctober 9, 2024 | globenewswire.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading Up 4.2% - Here's WhyORIC Pharmaceuticals (NASDAQ:ORIC) Trading Up 4.2% - Here's WhyOctober 8, 2024 | marketbeat.comWedbush Sticks to Its Buy Rating for Scholar Rock Holding (SRRK)October 7, 2024 | markets.businessinsider.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)October 4, 2024 | globenewswire.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Recommendation of "Buy" by BrokeragesORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) has been given an average recommendation of "Buy" by the seven research firms that are currently covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 12 month priceOctober 4, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 4.3%ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 4.3%October 2, 2024 | marketbeat.comFred Alger Management LLC Trims Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Fred Alger Management LLC cut its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 29.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 155,912 shares of the company's stock aftSeptember 28, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Curis (CRIS), Scholar Rock Holding (SRRK) and Travere Therapeutics (TVTX)September 27, 2024 | markets.businessinsider.comWedbush Keeps Their Buy Rating on AnaptysBio (ANAB)September 27, 2024 | markets.businessinsider.comBrokers Set Expectations for ORIC Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:ORIC)ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - Investment analysts at Cantor Fitzgerald dropped their FY2024 earnings estimates for shares of ORIC Pharmaceuticals in a report released on Monday, September 23rd. Cantor Fitzgerald analyst P. Agrawal now expects that the company will earnSeptember 25, 2024 | marketbeat.comBank of New York Mellon Corp Has $1.32 Million Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)Bank of New York Mellon Corp boosted its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 62.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 186,484 shares of the company's stSeptember 20, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading 11.6% Higher ORIC Pharmaceuticals (NASDAQ:ORIC) Trading Up 11.6%September 19, 2024 | marketbeat.comBuy Rating Affirmed for Oric Pharmaceuticals Amid Promising Collaborations and Strategic Clinical AdvancesSeptember 18, 2024 | markets.businessinsider.comORIC Pharmaceuticals (NASDAQ:ORIC) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a report on Wednesday.September 18, 2024 | marketbeat.comOpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery CollaborationSeptember 18, 2024 | finance.yahoo.comTD Asset Management Inc Decreases Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)TD Asset Management Inc lessened its stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 33.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 139,400 shares of the company's stock after sellingSeptember 15, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading 11.7% Higher ORIC Pharmaceuticals (NASDAQ:ORIC) Trading 11.7% HigherSeptember 13, 2024 | marketbeat.comFirst Turn Management LLC Buys 418,389 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)First Turn Management LLC boosted its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 38.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,515,960 shares of the compaSeptember 13, 2024 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 3.7% ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 3.7%September 12, 2024 | marketbeat.com Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address Did you know you can now trade Bitcoin in your regular brokerage account? (Ad)You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history! That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords… Heck, you don’t even need a crypto wallet! >> Tap here to sign up and join them for the imminent workshop ORIC Media Mentions By Week ORIC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORIC News Sentiment▼1.310.81▲Average Medical News Sentiment ORIC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORIC Articles This Week▼23▲ORIC Articles Average Week Get ORIC Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Catalyst Pharmaceuticals News Today Agios Pharmaceuticals News Today Amneal Pharmaceuticals News Today Protagonist Therapeutics News Today IDEAYA Biosciences News Today Centessa Pharmaceuticals News Today Longboard Pharmaceuticals News Today Wave Life Sciences News Today CG Oncology News Today Recursion Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORIC) was last updated on 12/12/2024 by MarketBeat.com Staff From Our PartnersEx-Lawyer turns $50k into $5 million tradingHe was a lawyer by day, secret trader by night...or in this case by lunch… With nothing but a laptop and a ...Investing Daily | SponsoredPrepare Now Before This Looming $2 Trillion D.C. ShockMillions of traders could get blindsided by this election-year shock on December 18th… And if you do nothin...Timothy Sykes | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ORIC Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
